What it is claimed to help
These are the uses attached to CJC-1295 in research, clinical practice, or marketing. Listing a claim is not endorsing it — tap any of them to see every other compound carrying the same claim.
What the human evidence actually is
Small, uncontrolled, foreign-registry or single-group human studies only.
Pharmacology, not outcomes. Phase 1 studies did show sustained increases in GH and IGF-1 in healthy adults, and with the DAC version those increases lasted days. What was never done: trials showing that this produces more muscle, less fat, better recovery or better sleep. Raising a hormone level is not the same as improving an outcome.
How it is supposed to work
Binds the GHRH receptor; the DAC variant covalently binds serum albumin, extending half-life from minutes to days.
Safety
Phase 1 reported injection site reactions and flushing. One clinical development programme was discontinued. Long-term consequences of sustained elevated GH/IGF-1 are unstudied.
Storage and handling
Lyophilised peptide is generally stored at 2–8 °C, or below −20 °C for long-term storage. Reconstituted in bacteriostatic water (0.9% benzyl alcohol) a solution is typically treated as usable for about 28 days refrigerated, versus roughly 24 hours for plain sterile water, which has no preservative. Add the water slowly down the vial wall and swirl — never shake, which shears peptide chains and foams the solution.
Whatever number a protocol or a prescriber gave you, converting it into syringe units is where a misplaced decimal becomes a tenfold error. Our calculators do that conversion and nothing else — they never invent a dose.
Open the calculatorsSources
- Teichman SL et al. CJC-1295 phase 1, J Clin Endocrinol Metab 2006
- FDA 503A bulks list Category 2 removal notice, September 2024
- WADA Prohibited List
Verified against primary sources on 27 August 2026. Regulatory status in this field changes several times a year. See How We Rate Evidence.